Core Cancer Drug Scrutinized

SAN ANTONIO, Texas -- New findings suggest that the risks
associated with a class of chemotherapy drugs widely used to treat
breast cancer outweighed their benefits in some patients.

The
findings, presented at the San Antonio Breast Cancer Symposium on
Saturday, renewed a debate over whether the chemotherapy drugs
anthracyclines, which have been around since the 1960s, should remain
the standard of care in treating breast cancer, or whether newer drugs
should be used more frequently instead... Read More